All In Biotech

Drug Trial Radar · NCT03521037

Rucaparib Hepatic Impairment Study in Patients With a Solid Tumor

A Phase 1, Open-Label, Parallel Group Study to Determine the Pharmacokinetics, Safety and Tolerability of Rucaparib in Patients With an Advanced Solid Tumor and Either Moderate Hepatic Impairment or Normal Hepatic Function

Last checked: Nov 20, 2026Latest source record: Jun 9, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

16

Actual

Start

Feb 27, 2018

Primary completion

Sep 27, 2019

Study completion Feb 24, 2021

Sponsor

Lead sponsor
pharmaand GmbHIndustry
Sponsor type
Industry
First posted
May 11, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 1, open-label, parallel group, PK, safety and tolerability study in patients with an advanced solid tumor and either normal hepatic function (Group 1, n = 8) or moderate hepatic impairment (Group 2, n = 8) according to the NCI-ODWG criteria. Patients in Group 1 and Group 2 may be enrolled in parallel, with preferential enrollment of Group 2 patients before Group 1 patients. The study will consist of 2 parts: a single-dose PK part (Part I) and a continuous rucaparib treatment part (Part II).

Conditions

  • Neoplasms

Interventions

  • Rucaparib camsylateDrug

    In Part I, eligible patients will receive a single oral dose of 600 mg rucaparib followed by intensive plasma PK sampling up to Day 7 (hour 144). In Part II, patients may continue to receive continuous oral rucaparib in 28 day cycles.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum plasma rucaparib concentration (Cmax)Time frame: day 1 to day 7
  2. Area under the plasma rucaparib concentration-time curve from time zero up to the last time point with quantifiable concentration (AUC0-last)Time frame: day 1 to day 7

Locations

6 sites in 3 countries. Site status is shown where the registry gives one.

  • Wojewódzki Szpital Specjalistyczny w Białej Podlaskiej

    Biała Podlaska, Poland

  • Med Polonia Sp. z o.o.

    Poznan, Poland

  • Zachodniopomorskie Centrum Onkologii w Szczecinie

    Szczecin, Poland

  • BioVirtus Centrum Medyczne

    Warsaw, Poland

  • Summit Clinical Research s.r.o.

    Bratislava, Slovakia

  • Northern Centre for Cancer Care

    Newcastle upon Tyne, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.